Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
GoodRx Holdings has delivered a steep 89.7% share price decline over the past five years. The stock has recently bounced, which sits awkwardly with valuation checks that currently lean toward the shares looking expensive rather than clearly mispriced on the downside.
-
The stock is down 89.7% over five years, which suggests long term holders have worn a heavy loss despite the recent short term recovery.
-
Future progress on converting its platform usage into consistent cash generation can support the current price, while any setback in margins or user engagement may quickly call that support into question.
-
GoodRx Holdings passes only 2 of 6 valuation checks , which points to a low overall value score and a stock that does not screen as a clear bargain on the broader metrics.
The issue now is whether the recent share price recovery leaves GoodRx Holdings overvalued relative to what its fundamentals appear to justify.
Is GoodRx Holdings Getting Expensive on Earnings?
The P/E ratio is the cleanest way to see what you are paying today for each dollar of GoodRx Holdings earnings. On this metric, the stock trades on about 75.4x earnings, which is well above the Healthcare Services industry average of roughly 27.8x and higher than the peer group average of about 50.6x.
The tailored fair P/E multiple for GoodRx Holdings, which adjusts for its growth profile, margins, size and risk, sits near 37.5x. That is roughly half of where the shares change hands today and indicates that the market is pricing in a lot of optimism already. For anyone looking at GoodRx Holdings mainly through an earnings lens, the gap between the current P/E and this fair ratio points to a rich valuation rather than a clear bargain.
On the P/E multiple alone, GoodRx Holdings stock currently appears overvalued.
See what the numbers say about this price — find out in our valuation breakdown.
The GoodRx Holdings Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for GoodRx Holdings pick up from this valuation puzzle and explain which future paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today, based on different sets of assumptions. Each Narrative treats GoodRx Holdings' fair value as a thesis about how the business might develop that you can track over time, rather than a one off snapshot.
Community views on GoodRx Holdings sit on opposite sides of the spectrum, with one camp focused on membership upside and the other on structural risks.
Bull case: 10% undervalued
"GoodRx's entry and rapid expansion in the high-growth subscription market ... positions it to capture large, recurring revenue streams with far higher gross margins than transaction-based business, accelerating earnings and margin expansion..."
Read the full Bull Case to see why GoodRx Holdings could be undervalued
Bear case: 44% overvalued
"Continued industry consolidation among pharmacies, PBMs, and insurance providers could eliminate the market for third-party coupon and discount programs altogether, narrowing GoodRx's addressable market and putting long-term earnings growth at risk..."
Read the full Bear Case to see why GoodRx Holdings could be overvalued
Do you think there's more to the story for GoodRx Holdings? Head over to our Community to see what others are saying!
The Bottom Line
GoodRx Holdings currently screens as overvalued on market multiples, with the share price sitting well above the tailored P/E guide that its fundamentals suggest. The key question from here is whether GoodRx Holdings can convert its platform usage into steadier earnings and stronger margins that eventually justify this richer multiple. If that earnings and margin story falls short, today's valuation leaves limited room for disappointment.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GDRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
